Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.
Daponte A, Signoriello S, Maiorino L, Massidda B, Simeone E, Grimaldi AM, Caracò C, Palmieri G, Cossu A, Botti G, Petrillo A, Lastoria S, Cavalcanti E, Aprea P, Mozzillo N, Gallo C, Comella G, Ascierto PA; Southern Italy Cooperative Oncology Group (SICOG). Daponte A, et al. Among authors: cavalcanti e. J Transl Med. 2013 Feb 13;11:38. doi: 10.1186/1479-5876-11-38. J Transl Med. 2013. PMID: 23402397 Free PMC article. Clinical Trial.
Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial.
Capasso I, Esposito E, Maurea N, Montella M, Crispo A, De Laurentiis M, D'Aiuto M, Frasci G, Botti G, Grimaldi M, Cavalcanti E, Esposito G, Fucito A, Brillante G, D'Aiuto G, Ciliberto G. Capasso I, et al. Among authors: cavalcanti e. Trials. 2013 Aug 28;14:273. doi: 10.1186/1745-6215-14-273. Trials. 2013. PMID: 23981814 Free PMC article. Clinical Trial.
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.
Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA. Simeone E, et al. Among authors: cavalcanti e. Cancer Immunol Immunother. 2014 Jul;63(7):675-83. doi: 10.1007/s00262-014-1545-8. Epub 2014 Apr 3. Cancer Immunol Immunother. 2014. PMID: 24695951 Free PMC article.
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.
Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero MV, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA. Caputo E, et al. Among authors: cavalcanti e. J Transl Med. 2014 Jul 31;12:216. doi: 10.1186/s12967-014-0216-z. J Transl Med. 2014. PMID: 25074438 Free PMC article.
Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype.
Capasso I, Esposito E, de Laurentiis M, Maurea N, Cavalcanti E, Botti G, Petrillo A, Montella M, D'Aiuto M, Coppola C, Crispo A, Grimaldi M, Frasci G, Fucito A, Ciliberto G, D'Aiuto G. Capasso I, et al. Among authors: cavalcanti e. Diabetol Metab Syndr. 2014 Sep 26;6(1):105. doi: 10.1186/1758-5996-6-105. eCollection 2014. Diabetol Metab Syndr. 2014. PMID: 25285159 Free PMC article.
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).
Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Terranova Barberio M, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A. Avallone A, et al. Among authors: cavalcanti e. BMC Cancer. 2014 Nov 24;14:875. doi: 10.1186/1471-2407-14-875. BMC Cancer. 2014. PMID: 25421252 Free PMC article. Clinical Trial.
Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.
Caputo E, Wang E, Valentino A, Crispi S, De Giorgi V, Fico A, Ficili B, Capone M, Anniciello A, Cavalcanti E, Botti G, Mozzillo N, Ascierto PA, Marincola FM, Travali S. Caputo E, et al. Among authors: cavalcanti e. Cancer Lett. 2015 Feb 1;357(1):286-296. doi: 10.1016/j.canlet.2014.11.033. Epub 2014 Nov 20. Cancer Lett. 2015. PMID: 25444926 Free PMC article.
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
Avallone A, Piccirillo MC, Aloj L, Nasti G, Delrio P, Izzo F, Di Gennaro E, Tatangelo F, Granata V, Cavalcanti E, Maiolino P, Bianco F, Aprea P, De Bellis M, Pecori B, Rosati G, Carlomagno C, Bertolini A, Gallo C, Romano C, Leone A, Caracò C, de Lutio di Castelguidone E, Daniele G, Catalano O, Botti G, Petrillo A, Romano GM, Iaffaioli VR, Lastoria S, Perrone F, Budillon A. Avallone A, et al. Among authors: cavalcanti e. BMC Cancer. 2016 Feb 8;16:69. doi: 10.1186/s12885-016-2102-y. BMC Cancer. 2016. PMID: 26857924 Free PMC article. Clinical Trial.
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, Maglione MG, Di Marzo M, Muto P, Cavalcanti E, Petrillo A, Sandomenico F, Maiolino P, D'Aniello R, Botti G, De Cecio R, Losito NS, Scala S, Trotta A, Zotti AI, Bruzzese F, Daponte A, Calogero E, Montano M, Pontone M, De Feo G, Perri F, Budillon A. Caponigro F, et al. Among authors: cavalcanti e. BMC Cancer. 2016 Nov 25;16(1):918. doi: 10.1186/s12885-016-2957-y. BMC Cancer. 2016. PMID: 27884140 Free PMC article. Clinical Trial.
188 results